Bladder Cancer

Latest News

UGN-102 demonstrates long-term durability in NMIBC
UGN-102 demonstrates long-term durability in NMIBC

June 13th 2024

The 12-month duration of response was 82.3% among patients with LG-IR-NMIBC who achieved a complete response at 3 months following the first UGN-102 instillation.

Cretostimogene Grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC
Cretostimogene Grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC

June 5th 2024

Sacituzumab govitecan falls short in phase 3 trial for metastatic urothelial carcinoma
Sacituzumab govitecan falls short in phase 3 trial for metastatic urothelial carcinoma

May 31st 2024

Nivolumab plus chemotherapy approved in EU for urothelial carcinoma
Nivolumab plus chemotherapy approved in EU for urothelial carcinoma

May 29th 2024

Expert discusses gender disparities in bladder cancer care
Expert discusses gender disparities in bladder cancer care

May 27th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.